Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Ulcerative Colitis: HELP
Articles from Ukraine
Based on 12 articles published since 2010
||||

These are the 12 published articles about Colitis, Ulcerative that originated from Ukraine during 2010-2020.
 
+ Citations + Abstracts
1 Clinical Trial Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis. 2019

Kruis, Wolfgang / Neshta, Viacheslav / Pesegova, Marina / Alekseeva, Olga / Andreev, Pavel / Datsenko, Oleksii / Levchenko, Olena / Abdulkhakov, Sayar / Lozynskyy, Yuriy / Mostovoy, Yuriy / Soloviev, Konstantin / Dorofeyev, Andrey E / Vieth, Michael / Stiess, Michael / Greinwald, Roland / Mohrbacher, Ralf / Siegmund, Britta. ·Medical Department, Evangelisches Krankenhaus Kalk, Cologne, Germany. Electronic address: wolfgang.kruis@googlemail.com. · Departmental Clinical Hospital of Railway Station Zaporizhzhya-2 State Enterprise "PrydniprovskaZaliznytsya," Zaporizhya, Ukraine. · Regional Clinical Hospital, Krasnoyarsk, Russia. · Nizhny Novgorod Regional Clinical Hospital Semashko, Nizhny Novgorod, Russia. · Railway Clinical Hospital on Station Samara, Samara, Russia. · Kharkiv City Clinical Hospital #2, Kharkiv, Ukraine. · Odesa Regional Clinical Hospital, Odesa, Ukraine. · Kazan (Volga Region) Federal University, and Kazan State Medical University, Kazan, Russia. · Lviv Regional Clinical Hospital, Lviv, Ukraine. · Private Small-Scale Enterprise Pulse, Vinnitsya, Ukraine. · Novgorod Regional Clinical Hospital, VeliklyNovogorod, Russia. · National Medical University, Kyiv, Ukraine. · Institute of Pathology, Klinikum Bayreuth, Bayreuth, Germany. · Research and Development, Dr. Falk Pharma GmbH, Freiburg, Germany. · Medizinische Klinik für Gastroenterologie, Infektiologie, Rheumatologie, Charité-Universitätsmedizin Berlin, Berlin, Germany. ·Clin Gastroenterol Hepatol · Pubmed #29702300.

ABSTRACT: BACKGROUND & AIMS: Although proctitis is the most limited form of ulcerative colitis, it causes unpleasant symptoms. Topical mesalamine, the standard treatment, is not always effective. We conducted a randomized phase 2 trial to determine the efficacy and safety of 2 doses of a budesonide suppository vs mesalamine suppositories vs combined budesonide and mesalamine suppositories for proctitis. METHODS: We performed a prospective, double-blind, double-dummy, multicenter trial in 337 patients with active proctitis to compare the efficacies of 4 different suppository treatments. Patients were randomly assigned to groups given 2 mg budesonide suppositories (2 mg BUS; n = 89 patients), 4 mg BUS (n = 79), 1 g mesalamine suppositories (1 g MES; n = 81), or the combination of 2 mg BUS and 1 g MES (n = 88). The study was performed from November 2013 through July 2015 at 36 study sites in Europe and Russia. The primary end point was the time to resolution of clinical symptoms, defined as the first of 3 consecutive days with a score of 0 for rectal bleeding and stool frequency. RESULTS: The mean time to resolution of symptoms in the 4 mg BUS (29.8 days) and combination of 2 mg BUS and 1 g MES (29.3 days) groups resembled that of the standard 1 g MES treatment (29.2 days), but was significantly longer in the 2 mg BUS group (35.5 days). Furthermore, proportions of patients with deep, clinical, and endoscopic remission, as well as mucosal healing, were similar among the 1 g MES, 4 mg BUS, and combination therapy groups, but significantly lower in the group that received 2 mg BUS. No safety signals were observed, and the patients' treatment acceptance was high (67%-85% of patients). CONCLUSIONS: In a multicenter randomized trial, we found that the efficacy and safety of 4 mg BUS in treatment of active proctitis did not differ significantly from those of 1 g MES. Budesonide suppositories offer an alternative therapy to mesalamine for topical treatment of proctitis. Clinicaltrialsregister.eu no: 2012-003362-41.

2 Clinical Trial Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. 2017

D'Haens, G R / Sandborn, W J / Zou, G / Stitt, L W / Rutgeerts, P J / Gilgen, D / Jairath, V / Hindryckx, P / Shackelton, L M / Vandervoort, M K / Parker, C E / Muller, C / Pai, R K / Levchenko, O / Marakhouski, Y / Horynski, M / Mikhailova, E / Kharchenko, N / Pimanov, S / Feagan, B G. ·Amsterdam, The Netherlands. · London, ON, Canada. · La Jolla, CA, USA. · Leuven, Belgium. · Rheinfelden, Switzerland. · Ghent, Belgium. · Scottsdale, AZ, USA. · Odessa, Ukraine. · Minsk, Belarus. · Sopot, Poland. · Gomel, Belarus. · Kiev, Ukraine. · Vitebsk, Belarus. ·Aliment Pharmacol Ther · Pubmed #28568974.

ABSTRACT: BACKGROUND: High concentration mesalazine formulations are more convenient than conventional low concentration formulations for the treatment of ulcerative colitis (UC). AIM: To compare the efficacy and safety of 1600 mg and 400 mg tablet mesalazine formulations. METHODS: Patients with mild-to-moderate active UC (Mayo Clinic Score >5; N=817) were randomised to 3.2 g of oral mesalazine, administered as two 1600 mg tablets once, or four 400 mg tablets twice daily. We hypothesised that treatment with the 1600 mg tablet was non-inferior (within a 10% margin) to the 400 mg tablet for induction of clinical and endoscopic remission at week 8. Open-label treatment with the 1600 mg tablet continued for 26-30 weeks based on induction response. Predictors of treatment response were also explored. RESULTS: At week 8, remission occurred in 22.4% and 24.6% of patients receiving the 1600 mg and 400 mg tablets, respectively (absolute difference -2.2%, 95% CI: -8.1% to 3.8%, non-inferiority P=.005). Endoscopic and histopathologic disease activity, leucocyte concentration and age were significantly associated with clinical remission (P=.022, .042, .014 and .023, respectively). At week 38, 43.9% (296/675) of patients who continued treatment with the 1600 mg formulation were in remission, including 70.3% (142/202) of patients who received a reduced dose of mesalazine (1.6 g/d). The overall incidence of serious adverse events was low. CONCLUSIONS: Induction therapy with 3.2 mg mesalazine using two 1600 mg tablets once-daily was statistically and clinically non-inferior to a twice-daily regimen using four 400 mg tablets (NCT01903252).

3 Article Comparison of the effects of tofacitinib and adalimumab on transcolonoscopic ph and calprotectin levels in patients with ulcerative colitis. 2020

Varvarynets, Antonina V / Chubirko, Ksenija I / Chopey, Ivan V / Hnepa, Yana Y / Kurakh, Artur V. ·Shei «Uzhhorod National University», Uzhhorod, Ukraine. ·Wiad Lek · Pubmed #32285809.

ABSTRACT: OBJECTIVE: The aim: To investigate the transcolonoscopic pH-metry and calprotectin in patients with ulcerative colitis. PATIENTS AND METHODS: Materials and methods: the research included 110 patients both male and female between the ages of 18 to 75 years old, who were treated for UC of medium and severe activity, in active phase. All patients were divided into 3 groups. The first group received standard therapy (ST; n=50), the second group received adalimumab (ADA; n=32), and the third group was treated with tofacitinib (TOF; n=28). The control group consisted of healthy individuals between the ages of 18 and 65 years old. RESULTS: Results: UC patients had lower pH levels in all sections of the large intestine, compared to the control group (р<0,05). Calprotectin level is a better predictor of the course of the disease. CONCLUSION: Conclusions:Tofacitinib, compared to adalimumab and budesonide, has better influence on clinical, endoscopic and laboratory parameters of UC.

4 Article Genetic polymorphism in patients with early and late onset of ulcerative colitis. 2020

Dorofeyev, Andriy E / Dorofeyeva, Anna A / Kiriyan, Elena A / Rassokhina, Olga A / Dynia, Yulia Z. ·Shupyk National Medical Academy Of Postgraduate Education, Kyiv, Ukraine. · Institute Of Gerontology N.A. D.F.Chebotarev, Kyiv, Ukraine. · Ukrainian Medical And Dental Academy, Poltava, Ukraine. · Donetsk National Medical University, Liman, Ukraine. ·Wiad Lek · Pubmed #32124813.

ABSTRACT: OBJECTIVE: The aim was to investigate SNPs of TLR-2,3,4, NOD2/CARD15, JAK-2, and IL-10 in patients with the early and late UC onset. PATIENTS AND METHODS: Matherials and methods: 126 patients with UC were investigated. To assess the predisposition of the early and late UC onset the incidence of the following SNPs: Arg753Gln TLR2 gene, Phe412Leu TLR3 gene, Asp299Gly and Thr399Ile TLR4 gene, C-819T, G-1082A and C-592A gene IL-10, Val617Phe gene JAK2, Gly908Arg gene NOD2/CARD15 were analyzed. RESULTS: Results: 76 patients had early disease onset and 50 had a late one. SNPs of TLR3 were observed in 50.8% cases. TLR4 polymorphism was more common than TLR3, and was observed in 81 (64.3%) UC patients. Polymorphism of NOD2/CARD15 and IL-10 genes were revealed with almost the same frequency 49 (38.9%) and 50 (39.9%) patients, respectively. CONCLUSION: Conclusions: Polymorphisms of TLR-2,3 genes and TLR4 Asp299Gly, NOD2/CARD15 prevailed in patients with the late UC onset that allows to suppose that bacterial flora plays one of the key roles in modification of immune response and UC development. In patients with early UC onset polymorphisms of the JAK2 and IL-10 genes prevailed responsible for the cytokine cascade activation and cause the immune mechanism that might lead to a more aggressive course of the disease.

5 Article Effect of С 2018

Byelinska, I V / Kuznietsova, H M / Dziubenko, N V / Lynchak, O V / Rybalchenko, T V / Prylutskyy, Yu I / Kyzyma, O A / Ivankov, O / Rybalchenko, V K / Ritter, U. ·Taras Shevchenko National University of Kyiv, 64/13, Volodymyrska str., 01601 Kyiv, Ukraine. Electronic address: byelinska@univ.kiev.ua. · Taras Shevchenko National University of Kyiv, 64/13, Volodymyrska str., 01601 Kyiv, Ukraine. · Taras Shevchenko National University of Kyiv, 64/13, Volodymyrska str., 01601 Kyiv, Ukraine; Joint Institute for Nuclear Research, Dubna, Moscow Region, Russia. · Joint Institute for Nuclear Research, Dubna, Moscow Region, Russia. · Technical University of Ilmenau, Institute of Chemistry and Biotechnology, 25 Weimarer str., 98693 Ilmenau, Germany. ·Mater Sci Eng C Mater Biol Appl · Pubmed #30274084.

ABSTRACT: The application of pristine С

6 Article [Clinical and endoscopic efficacy of vedolizumab in patients with ulcerative colitis]. 2018

Varvarynets, Antonina V / Chopei, Ivan V / Chubirko, Kseniya I. ·Department Of Therapy And Family Medicine, Faculty Of Postgraduate Education And Pre-University Training, Uzhhorod National University, Uzhhorod, Ukraine. ·Wiad Lek · Pubmed #29729171.

ABSTRACT: OBJECTIVE: Introduction: Ulcerative colitis (UC) is a chronic recurrent idiopathic inflammatory bowel disease that is characterized by a continuous or wave-like course with multifactorial etiopathogenesis. In recent decades, the number of patients with this pathology has been steadily increasing. Therefore, timely detection of UC at the diagnostic stage for the further qualified assistance providing is one of the most important tasks in modern gastroenterology. In recent years, a new group of drugs that can be an alternative to the surgical method of treatment has appeared. These are biological drugs, one of which is vedolizumab. The aim: to study the changes in clinical and endoscopic parameters in patients with ulcerative colitis, in response to the biological therapy with vedolizumab. PATIENTS AND METHODS: Materials and methods: 38 patients with ulcerative colitis were included in this study that lasted 52 weeks. 15 patients of the control group received standard therapy with 5-aminosalicylic acid (5-ASA). 23 patients in the study group received the vedolizumab infusions. RESULTS: Results: Clinical response was observed in 16 (69.6%) and 23 (100.0%) patients of the study group at the 6th and 52nd weeks respectively. In control group the clinical response was present in 5 (33.3%) and 9 (60,0%) patients at the 6th and 52nd weeks respectively. Mucosal healing at the 52nd week was observed in 22 (95.7%) patients in the study group and 7 (46.7%) patients in the control group. CONCLUSION: Conclusions: Patients who were treated with vedolizumab experienced significant improvement in clinical and endoscopic parameters 52 weeks after treatment initiation compared to the control group.

7 Article Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. 2018

Dignass, Axel / Schnabel, Robert / Romatowski, Jacek / Pavlenko, Vladimir / Dorofeyev, Andrey / Derova, Jelena / Jonaitis, Laimas / Dilger, Karin / Nacak, Tanju / Greinwald, Roland / Anonymous9230936. ·Department of Medicine 1, Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany. · Pannónia Magánorvosi Centrum Kft, Budapest, Hungary. · Gastromed sc, Bialystok, Poland. · State Budgetary Educational Institution of Higher Professional Education, Stavropol, Russian Federation. · Regional Bowel Diseases Centre, Donetsk State Medical University, Donetsk, Ukraine. · Latvian Maritime Medical Centre, Riga, Latvia. · Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania. · Drug Safety, Dr Falk Pharma GmbH, Freiburg, Germany. · Clinical Research and Development Department, Dr Falk Pharma GmbH, Freiburg, Germany. ·United European Gastroenterol J · Pubmed #29435324.

ABSTRACT: Background: Adherence to mesalazine treatment is essential for the successful treatment of ulcerative colitis. Objective: The objective of this study was to compare the efficacy, safety and preference of a novel high-dose 1000 mg mesalazine tablet versus conventional treatment for ulcerative colitis remission. Methods: This pivotal phase III trial compared one 1000 mg mesalazine tablet (M1000 group) versus two registered 500 mg mesalazine tablets (M2x500 group), both taken three times daily, in patients with mild to moderately active ulcerative colitis. The primary efficacy variable was clinical remission at week 8. Results: A total of 306 patients were considered for intent-to-treat analysis. Clinical remission was achieved in 45.0% of the patients in the M1000 group versus 41.9% in the M2x500 group ( Conclusions: The novel high-dose 1000 mg mesalazine tablet is effective, non-inferior to the registered 500 mg mesalazine tablet, and safe for ulcerative colitis treatment. It was preferred by a majority of patients and may improve ulcerative colitis treatment adherence.

8 Article Efficiency comparison of tofacitinib and budesonid in treatment of nonspecific ulcerative colitis. 2017

Bratasiuk, Andriy M / Niroda, Antonina I. ·State Higher Education Establishment "Uzhhorod National University", Faculty Of Postgraduate Education And Pre-University Training, Department Of Therapy And Family Medicine, Uzhhorod, Ukraine. ·Wiad Lek · Pubmed #28511169.

ABSTRACT: INTRODUCTION: A constant interest to explore NUC is caused by the global trend showing a rise in colitis mobidity rate. According to a series of epidemiological studies, the highest incidence of NUC occurs in young age groups, which leads to significant loss of working capacity and high level of incapacitation. One of the leading roles in the pathogenesis of this disease is reportedly played by immunogenetic theory. To date, the main practical technique of NUC diagnostics is colonoscopy. To assess the activity level, the Mayo score is used most frequently. The aim of NUC treatment is to achieve and maintain remission as well as improve the patients' life quality. One of the main achievements of contemporary gastroenterology is practical introduction of such high-performance preparations as mononuclear antibodies to TNF- α. AIM: To compare the impact of tofacitinib and budesonid on the mucous membrane of NUC patients. MATERIAL AND METHODS: Over the past two years 498 colonoscopic surveys have been performed at the Therapeutics Department of Uzhhorod Central Rayon Hospital, of which 16 patients have been chosen. Depending upon the treatment obtained, all the patients were divided into two groups: Group I - patients that were taking tofacitinib in constant doses of 10 mg/day; Group II - patients that were taking budesonid in doses of 9 mg/day. The Mayo score was used to assess the level of inflammation activity. RESULTS: By morbidity occurrence, proctosigmoiditis was diagnosticated in 5 (31.25%), sinistral colitis in 7 (43.75%), and total colitis in 4 (25.00%) patients. The values of the integrative Mayo index at the moment of primary examination were 8.89±1.17 and 8.29±1.11 in Groups I and II, correspondingly. The treatment with budesonid led to a 15.56% decline in inflammation activity, equaling to 7.00±1.15 points of the Mayo score. In response to the treatment with tofacitinib the value went down by 59.96%, equaling to 3.56±1.13 points of the Mayo score, which was reliably lower as compared with Group II ( р<0.05). CONCLUSIONS: The use of tofacitinib was observed to result in a reliably better curative effect as compared with budesonid, which fact was verified endoscopically.

9 Article Late-Onset of Acute Severe Ulcerative Colitis: Clinical Case. 2017

Dorofeyev, A E / Rassokhina, O A / Dorofeyeva, A A. ·National Medical University n.a.A.A.Bogomoletz, Kiev, Ukraine. ·Dig Dis · Pubmed #28147350.

ABSTRACT: Ulcerative colitis (UC) in adult age requires more careful examination because more often it turns out to be a complication related to the precancer condition. The onset of colitis in older age is predicted to follow a more aggressive clinical course and requires more frequent hospitalizations and steroids prescription in contrast to its onset in young patients. Even as this remains unclear, we present here a clinical case of late onset of acute severe UC to represent interesting clinical peculiarities and response to the therapy. Patient P., a 57-year-old male complained of 8 days of bloody diarrhea and lower abdominal pain. He reported having up to 3-5 urgent stool per day and 3-4 stool per night weight loss with dehydration. Stool culture was negative for infection, but fecal leukocytes were present. Flexible colonoscopy and biopsies were performed, which showed friable and erythematous mucosa with erosions and ulcers in a diffuse circumferential distribution from the anal verge to the cecum. There were no pseudomembranes. Histological evaluation revealed acute inflammation without architectural distortion consistent with either acute infectious colitis or new inflammatory bowel disease, favoring UC. Treatment for presumed UC is initiated with mesalazine 8 g daily: 4 g orally, 4 g per rectum and prednisone at 40 mg orally daily. After 48 h, stool frequency was 12 times per day (2 per night) with urgency, and blood was seen in stool occasionally. Intravenous steroids were prescribed - 16 mg of dexamethasone. After 48 h, stool frequency reduced to 8 per day, 1-2 per night, with traces of blood in stool and general well-being was increased. But after 14 days, the condition did not change significantly. Infliximab 5 mg/kg was administered and after the first infusion, stool frequency reduced to 4 times per day without urgency and night diarrhea. Azathioprine 100 mg per day was prescribed after steroid (prednisone) withdrawal. But after the third infusion of infliximab, the patient felt pain along the intercostal nerves along with skin redness and itching. Herpes zoster virus infection was diagnosed. Famciclovir 750 mg per day was prescribed, azathioprine was stopped, infusions of infliximab were continued and after 12 months, patient was started on a monotherapy of infliximab 1 time per 8 weeks and he had stable remission.

10 Article Anti-Inflammatory Effects of Protein Kinase Inhibitor Pyrrol Derivate. 2016

Kuznietsova, Halyna M / Yena, Maryna S / Kotlyar, Iryna P / Ogloblya, Olexandr V / Rybalchenko, Volodymyr K. ·Institute of Biology, Taras Shevchenko National University, Volodymyrska 64/13, Kyiv 01601, Ukraine. ·ScientificWorldJournal · Pubmed #28101521.

ABSTRACT: In our previous studies we showed antitumor and anti-inflammatory activities of protein kinases inhibitor pyrrol derivate 1-(4-Cl-benzyl)-3-Cl-4-(CF3-fenylamino)-1H-pyrrol-2,5-dione (MI-1) on rat colon cancer model. Therefore anti-inflammatory effect of MI-1 on rat acetic acid induced ulcerative colitis (UC) model was aimed to be discovered. The anti-inflammatory effects of MI-1 (2.7 mg/kg daily) compared to reference drug Prednisolone (0.7 mg/kg daily) after 14-day usage were evaluated on macro- and light microscopy levels and expressed in 21-grade scale. Redox status of bowel mucosa was also estimated. It was shown that in UC group the grade of total injury (GTI) was equal to 9.6 (GTI

11 Article Role of Dopamine and D2 Dopamine Receptor in the Pathogenesis of Inflammatory Bowel Disease. 2015

Tolstanova, Ganna / Deng, Xiaoming / Ahluwalia, Amrita / Paunovic, Brankica / Prysiazhniuk, Alona / Ostapchenko, Lyudmyla / Tarnawski, Andrzej / Sandor, Zsuzsanna / Szabo, Sandor. ·VA Long Beach Healthcare System, Departments of Medicine, Pathology and Pharmacology, VA Medical Center (05/113), University of California-Irvine, 5901 East 7th Street, Long Beach, CA, 90822, USA. gtolstanova@gmail.com. · Educational-Scientific Center "Institute of Biology", Taras Shevchenko National University of Kyiv, Kiev, Ukraine. gtolstanova@gmail.com. · VA Long Beach Healthcare System, Departments of Medicine, Pathology and Pharmacology, VA Medical Center (05/113), University of California-Irvine, 5901 East 7th Street, Long Beach, CA, 90822, USA. · Educational-Scientific Center "Institute of Biology", Taras Shevchenko National University of Kyiv, Kiev, Ukraine. · VA Long Beach Healthcare System, Departments of Medicine, Pathology and Pharmacology, VA Medical Center (05/113), University of California-Irvine, 5901 East 7th Street, Long Beach, CA, 90822, USA. sszabo@uci.edu. ·Dig Dis Sci · Pubmed #25972152.

ABSTRACT: BACKGROUND: VEGF-induced vascular permeability and blood vessels remodeling are key features of inflammatory bowel disease (IBD) pathogenesis. Dopamine through D2 receptor (D2R) inhibits VEGF/VPF-mediated vascular permeability and angiogenesis in tumor models. In this study, we tested the hypothesis that pathogenesis of IBD is characterized by the disturbance of dopaminergic system and D2R activity. METHODS: IL-10 knockout (KO) mice and rats with iodoacetamide-induced ulcerative colitis (UC) were treated intragastrically with D2R agonists quinpirole (1 mg/100 g) or cabergoline (1 or 5 µg/100 g). Macroscopic, histologic, and clinical features of IBD, colonic vascular permeability, and angiogenesis were examined. RESULTS: Although colonic D2R protein increased, levels of tyrosine hydroxylase and dopamine transporter DAT decreased in both models of IBD. Treatment with quinpirole decreased the size of colonic lesions in rats with iodoacetamide-induced UC (p < 0.01) and reduced colon wet weight in IL-10 KO mice (p < 0.05). Quinpirole decreased colonic vascular permeability (p < 0.001) via downregulation of c-Src and Akt phosphorylation. Cabergoline (5 µg/100 g) reduced vascular permeability but did not affect angiogenesis and improved signs of iodoacetamide-induced UC in rats (p < 0.05). CONCLUSIONS: Treatment with D2R agonists decreased the severity of UC in two animal models, in part, by attenuation of enhanced vascular permeability and prevention of excessive vascular leakage. Hence, the impairment dopaminergic system seems to be a feature of IBD pathogenesis.

12 Article Role of nitric oxide-synthase and cyclooxygenase/lipooxygenase systems in development of experimental ulcerative colitis. 2011

Sklyarov, A Ya / Panasyuk, N B / Fomenko, I S. ·Department of Biochemistry, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine. biochemistry@meta.ua ·J Physiol Pharmacol · Pubmed #21451211.

ABSTRACT: Development of ulcerative colitis was accompanied by the activation of iNOS/COX-2/5-LOX and increased contents of nitric oxide (NO), prostaglandin E₂ (PGE₂), and leukotriene B₄ (LTB₄). The following information was assessed: morphological changes, activity of nitric oxide-synthase, content of nitric oxide, and indexes of lipoperoxidation processes in the mucous membrane of the large intestine (MMLI). Colitis was induced in rats by intrarectal administration of 1 ml of 4% acetic acid. Aminoguanidine--selective inducible nitric oxide-synthase (iNOS) blocker, celecoxib--cyclooxygenase-2 (COX-2) inhibitor, indomethacin--non-selective COX inhibitor and AA-861--5-lipooxygenase (5-LOX) blocker were administered in 1 ml volumes per os 1 hour before and 24 hours after the intrarectal application of acetic acid. It was noticed that blockage of iNOS by aminoguanidine caused enhancement of cytoprotective mechanisms, reduction of iNOS activity and oxidative stress, and an increase in blood L-arginine level as compared to their respective indexes in colitis. Combined blockage of iNOS and COX-2 displayed additive character of their effect on the processes of lipoperoxidation and activity of iNOS. Combined blockage of iNOS, COX-2 and 5-LOX had a manifested cytoprotective effect under condition of ulcerative colitis and was accompanied by a sharp decline in NOS activity and oxidative stress. If each of these systems, iNOS/NO, COX-2/PGE₂ and 5-LOX/LTB₄ are simultaneously activated due to inflammation, they contribute to the destructive damage of the MMLI, development of oxidative stress, and affect components of the antioxidant protection system. The obtained results substantiate the relevance of treatment of the inflammatory processes with the use of medication capable of combined blockage of iNOS, COX-2, and 5-LOX.